Navin Fluorine International Limited (NFIL) has reported a robust performance for the second quarter, with significant growth in revenue and profitability. The company's consolidated net profit more than doubled, showcasing strong operational efficiency and market demand for its products.

Financial Highlights

NFIL's Q2 results demonstrate substantial year-over-year improvements:

The company's performance shows a significant leap in profitability, with net profit rising by 152% compared to the same quarter last year. Revenue growth of 46% indicates strong market demand and possibly increased market share.

Operational Performance

NFIL's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a remarkable increase of 130%, reaching ₹246.00 crore. The EBITDA margin expanded substantially from 20.70% to 32.46%, reflecting improved operational efficiency and potentially better pricing power.

Dividend Declaration

The Board of Directors has declared an interim dividend of ₹6.50 per share (325%) on equity shares with a face value of ₹2 each for the financial year 2025-26. This declaration signals confidence in the company's financial health and commitment to shareholder returns.

Capital Expansion Plans

NFIL has announced significant capital expenditure plans:

1. An investment of ₹236.50 crore for expanding HFC (Hydrofluorocarbon) capacity by up to 15,000 MTPA R32 equivalent quantity at its Surat unit. This expansion aims to cater to growing demand in both domestic and export markets.

2. A ₹75.00 crore investment for debottlenecking the Multi Purpose Plant facility at Dahej through its wholly-owned subsidiary, Navin Fluorine Advanced Sciences Limited. This initiative is expected to accommodate additional product manufacturing and expand the company's product portfolio.

Equity Allotment

On October 29, 2025, NFIL allotted 8,500 equity shares under its Employees' Stock Option Scheme 2017, increasing its paid-up share capital to ₹10,24,70,188.

Future Outlook

With these strategic investments and strong financial performance, Navin Fluorine International appears well-positioned for continued growth. The expansion in HFC capacity and the debottlenecking of the Multi Purpose Plant are expected to strengthen the company's market position and potentially lead to increased revenues in the coming quarters.

The company's focus on expanding its product range, particularly in fluoro intermediates for novel agrochemical products, indicates a strategy to deepen relationships with global innovators and diversify its revenue streams.

Navin Fluorine International Limited (NFIL) has announced the completion of construction for its new cGMP-4 facility in Dewas, marking a significant milestone in the company's expansion efforts. The facility, representing an investment of nearly ₹160 crores, is now ready for commissioning, with validation batches already underway for a European partner.

Facility Details and Investment

The new cGMP-4 facility is part of a larger capital expenditure plan totaling ₹288 crores, as previously disclosed by the company. The completed phase, with an investment of approximately ₹160 crores, represents the first stage of this ambitious project.

Strategic Importance

This state-of-the-art facility underscores Navin Fluorine's commitment to enhancing its manufacturing capabilities and meeting international quality standards. The cGMP (Current Good Manufacturing Practice) designation indicates that the facility adheres to strict regulatory requirements, which is crucial for serving global pharmaceutical markets.

European Partnership

NFIL has already commenced validation batches for a European partner at the new facility. This early engagement with an international client highlights the strategic importance of the Dewas plant in strengthening the company's position in the global market.

Phased Approach

The company has adopted a phased approach for the cGMP-4 facility:

Next Steps

While the facility has achieved commissioning readiness, Navin Fluorine has stated that it will separately announce the commencement of commercial production. This suggests that the company is taking a methodical approach to ensure all quality and regulatory requirements are met before full-scale operations begin.

Company Statement

In its communication to the stock exchanges, Navin Fluorine International Limited stated, "Phase 1 of cGMP-4 with a capital expenditure of ~ Rs. 160 crores has achieved commissioning readiness today with validation batches having commenced for our European partner."

The completion of this facility marks a significant step for Navin Fluorine International in expanding its manufacturing footprint and potentially increasing its market share in the specialty chemicals and pharmaceutical intermediates sectors. Investors and industry observers will likely be watching closely for the announcement of commercial production commencement, which will signal the full realization of this substantial investment.